Acetylation attenuates polyamidoamine cytotoxicity

doi:10.3969/j.issn.2095-4344.2013.12.015

Abstract

Abstract:

BACKGROUND: Polyamidoamine dendrimer nanomaterials have been widely used in drug carrier research, but there are many electropositive amino groups on the surface of the entire generation polyamidoamine, resulting in certain cytotoxicity.
OBJECTIVE: To study the influence of acetylation on polyamidoamine cytotoxicity.
METHODS: (1) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay: the cell proliferation of 293T cells incubated with acetylated polyamidoamine under 0, 0.125, 0.25, 0.5, 1, 2, 4 μmol/L concentrations was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. (2) Cell morphology: the cell morphology of 293T cells incubated with 4 μmol/L acetylated polyamidoamine was observed by inverted fluorescence microscope. (3) Cell cycle: the cell cycle of 293T cells incubated with acetylatedpolyamidoamine under 0, 5, 10, 15, 20 mg/L concentrations was detected by flow cytometry.
RESULTS AND CONCLUSION: Polyamidoamine had cytotoxicity to 293T cells. The cell viability at 4 μmol/L concentration after 48 hours incubation was only 52%, and the acetylation could significantly decrease the cytotoxicity of polyamidoamine (P < 0.01). 293T cells incubated with polyamidoamine shrank and had bad stretching, while 293T cells incubated with acetylated polyamidoamine had good stretching. Acetylated polyamidoamine had no significant effect on the cell cycle, but polyamidoamine at 20 mg/L could block the cell cycle at S stage. All the results show that acetylation can decrease the cytotoxicity of polyamidoamine.

Key words: biomaterials, material biocompatibility, polyamidoamine, acetylation, cytotoxicity, 293T cells, proliferation, cell cycle, the National Natural Science Foundation of China, biomaterial photographs-containing paper

CLC Number:

R318

Acetylation attenuates polyamidoamine cytotoxicity. Acetylation attenuates polyamidoamine cytotoxicity[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(12): 2191-2196.

Figures/Tables 4

References

[1] Qu G,Wu X,Yin L,et al. N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics. Biomed Pharmacother.2012;66(1):46-51.

[2] Cosco D,Paolino D,Cilurzo F,et al.Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breastcancer diseases. Int J Pharm.2012; 422 (1-2):229-237.

[3] Nakagawa Y,Takayama K,Ueda H,et al.Preparation of bovine serum albumin nanospheres as drug targeting carriers. Drug Des Deliv.1987;2(2): 99-107.

[4] Sonaje K,Lin KJ,Wey SP,et al.Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials. 2010; 31(26): 6849-6858.

[5] Sudheesh MS,Vyas SP,Kohli DV.Nanoparticle-based immunopotentiation via tetanus toxoid-loaded gelatin and aminatedgelatin nanoparticles. Drug Deliv. 2011;18(5): 320-330.

[6] Hoffmann S,Vystr?ilová L,Ulbrich K,et al.Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging.Biomacromolecules. 2012;13(3): 652-663.

[7] Yoncheva K,Calleja P,Agüeros M,et al.Stabilized micelles as delivery vehicles for paclitaxel.Int J Pharm.2012;436(1-2): 258-264.

[8] Yuan W,Liu Z.Controlled-release and preserved bioactivity of proteins from (self-assembled) core-shell double-walled microspheres.Int J Nanomedicine. 2012;7:257-270.

[9] Puvanakrishnan P,Park J,Chatterjee D,et al.In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy.Int J Nanomedicine. 2012;7:1251-1258.

[10] Wahajuddin, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine.2012;7:3445-3471.

[11] Fabbro C,Ali-Boucetta H,Da Ros T,et al. Targeting carbon nanotubes against cancer.Chem Commun (Camb).2012; 48(33): 3911-3926.

[12] Tomalia D,Baker H,Dewald J,et al.A New Class of Polymers: Starburst-Dendritic Macromolecules. Polymer J.1985;17: 117-132.

[13] Paleos CM,Tsiourvas D,Sideratou Z,et al.Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Deliv. 2010;7(12):1387-1398.

[14] Yao W,Sun K,Mu H,et al.Preparation and characterization of puerarin–dendrimer complexes as an ocular drug delivery system. Drug Dev Ind Pharm.2010;36(9): 1027-1035.

[15] Rodrigo AC,Rivilla I,Pérez-Martínez FC,et al. Efficient, non-toxic hybrid PPV-PAMAM dendrimer as a gene carrier for neuronal cells. Biomacromolecules. 2011;12(4): 1205-1213 .

[16] Kumar A,Yellepeddi VK,Davies GE,et al.Enhanced gene transfection efficiency by polyamidoamine (PAMAM) dendrimers modified with ornithine residues.Int J Pharm. 2010;392(1-2): 294-303.

[17] Roberts JC,Bhalgat MK,Zera RT.Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers.J Biomed Mater Res.1996;30(1): 53-65.

[18] Malik N,Wiwattanapatapee R,Klopsch R,et al.Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release.2000; 65(1-2): 133-148.

[19] Hong S,Bielinska AU,Mecke A,et al.Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem. 2004;15(4): 774-782.

[20] Liu JF,Liu JJ,Chu LP,et al.Novel peptide-dendrimer conjugates as drug carrier for targeting nonsmall cell lung cancer. Int J Nanomed. 2011;6: 59-69.

[21] Singh P,Gupta U,Asthana A,et al.Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem.2008;19(11): 2239-2252.

[22] Zheng N,Dai W,Du W,et al. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors. Mol Pharm. 2012;9(5): 1175-1188.

[23] Wang J,Sui M,Fan W.Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab.2010; 11(2): 129-141.

[24] Ke W,Zhao Y,Huang R,et al.Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci. 2008;97(6): 2208-2216.

[25] Milhem OM,Myles C,McKeown NB,et al.Polyamidoamine Starburst dendrimers as solubility enhancers. Int J Pharm. 2000;197(1-2): 239-241.

[26] Kolhe P,Misra E,Kannan RM,et al. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm. 2003;259(1-2): 143-160.

[27] Zhu S,Hong M,Zhang L,et al.PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2010; 27(1): 161-174.

[28] Wiwattanapatapee R,Lomlim L,Saramunee K.Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid.J Control Release.2003;88(1): 1-9.